Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (July 2020)

29 slides from Aerie Pharmaceuticals's investor presentation, Jul 8, 2020

  1. Slide 1: Company Overview Investor Presentation July 2020

    Slide 1: Company Overview Investor Presentation July 2020

    Company Overview Investor Presentation July 2020 Exhibit 99.1

  2. Slide 2: Important Information

    Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    Aerie Overview Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indicat

  4. Slide 4: Aerie's Key Catalysts for 2020

    Slide 4: Aerie's Key Catalysts for 2020

    Aerie’s Key Catalysts for 2020 Pipeline: AR-15512 TRPM8 agonist for Dry Eye Phase 2b clinical study expected to commence Q4 2020 AR-1105 Phase 2 RVO clinical study readout expected Q3 2020 Globalization: Roclanda® Mercury 3 topline readout Q3 2020; Roclanda® EMA approval expected late 2020 / early 2

  5. Slide 5: Aerie Overview: U.S. Glaucoma Market

    Slide 5: Aerie Overview: U.S. Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

  6. Slide 6: 87% of OPH Offices are Currently Open

    Slide 6: 87% of OPH Offices are Currently Open

    87% of OPH Offices are Currently Open While a Variety of Mechanisms are Being Deployed COVID-19 IMPACT ON OFFICES 67% Offices only seeing “sick” patients 63% Office staff has been reduced 70% Offices have limited hours 13% Offices temporary closed 2% Business as usual 62% Offices using telehealth to

  7. Slide 7: Ophthalmologists Should Still be Accessible

    Slide 7: Ophthalmologists Should Still be Accessible

    Ophthalmologists Should Still be Accessible Even if Access Will be Different From the Past HOW WILL YOU INTERACT WITH PHARMACEUTICAL SALES REPRESENTATIVES IN THE FUTURE? MULTIPLE ANSWERS ALLOWED, SO TOTAL > 100% 15% Other – mix of face-to-face and virtual 3% No live or virtual contact with reps 6% I

  8. Slide 8: Aerie Franchise Fared Better Than Key Competitors

    Slide 8: Aerie Franchise Fared Better Than Key Competitors

    Comparing April to March, The Aerie Franchise Fared Better Than Key Competitors Product Mar-20 Apr-20 Chg % Change↓ Rhopressa® 31,451 28,219 -3,232 -10.3% Rocklatan® 14,858 13,157 -1,701 -11.4% Lumigan® 182,875 160,907 -21,968 -12.0% Simbrinza® 36,412 31,875 -4,537 -12.5% Combigan® 139,649 122,008 -

  9. Slide 9: COVID-19: How is Aerie Responding?

    Slide 9: COVID-19: How is Aerie Responding?

    COVID-19: How is Aerie Responding? Ongoing communication of the MOST Data Continued execution of the Pulse Strategy, focused on driving monthly prescribers to weekly prescribers (January to April gain of 700 HCP’s to over 4,200 weekly prescribers) Increasing share of voice with HCP’s to further bols

  10. Slide 10: Increasing Share of Voice

    Slide 10: Increasing Share of Voice

    Aerie reps calling on Top 10,000 highest prescribers Majority to be detailed 2x per month Added Contract Sales Organization to call on next 1,500 higher prescribing targets of glaucoma medications Added Telesales team to call on next 3,000 higher prescribing targets Goal: Increase Share of Voice wit

  11. Slide 11: Topline Results from Rhopressa MOST Study

    Slide 11: Topline Results from Rhopressa MOST Study

    Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

  12. Slide 12: U.S. Glaucoma Franchise: TRx/NRx % Change

    Slide 12: U.S. Glaucoma Franchise: TRx/NRx % Change

    U.S. Glaucoma Franchise: TRx/NRx % Change compared to prior week For Investor Use Source: IQVIA Rhopressa® bottles per Rx year-to-date 2020 were 1.38 (high as 1.43 in recent weeks) compared to same period 2019 of 1.27, reflecting an increase in 90 days’ supply. TRx% Change Versus Prior Week Week End

  13. Slide 13: U.S. Glaucoma Franchise Launch Update

    Slide 13: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 6/26/2020 IQVIA Weekl

  14. Slide 14: Advancing the Pipeline

    Slide 14: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

  15. Slide 15: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    Slide 15: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health

  16. Slide 16: AR-15512 for Dry Eye: Novel Mechanism of Action

    Slide 16: AR-15512 for Dry Eye: Novel Mechanism of Action

    AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear

  17. Slide 17: AR-15512 (TRPM8 Agonist) for Dry Eye

    Slide 17: AR-15512 (TRPM8 Agonist) for Dry Eye

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  18. Slide 18: AR-15512 for Dry Eye Phase 2a Study

    Slide 18: AR-15512 for Dry Eye Phase 2a Study

    AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t

  19. Slide 19: Efficacy for Symptoms with BID Dosing

    Slide 19: Efficacy for Symptoms with BID Dosing

    Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use ++Data on File Symptoms: SANDE Score Percentage of patients improving ≥20 score p=0.1 p=0.021 Graph on the right represents primary endpoint with a subset of more se

  20. Slide 20: Dry Eye Clinical Trial Highlights: Schirmer Evaluation

    Slide 20: Dry Eye Clinical Trial Highlights: Schirmer Evaluation

    ++Data on File For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days

  21. Slide 21: Dry Eye Program: AR-15512

    Slide 21: Dry Eye Program: AR-15512

    For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on

  22. Slide 22: AR-15512 Development Update

    Slide 22: AR-15512 Development Update

    For Investor Use AR-15512 Development Update 3-month toxicity studies ongoing FDA meeting held in June 2020 Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b study will evaluate efficacy and safety of 0.0014% and 0.003% BID First patient enrolled

  23. Slide 23: 2019 U.S. Retinal Disease Market

    Slide 23: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

  24. Slide 24: Aerie's Lead Implant Product Candidates

    Slide 24: Aerie's Lead Implant Product Candidates

    For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout Q3 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administrat

  25. Slide 25: Expanding Aerie Franchise: Japan

    Slide 25: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 Phase 3 trials expected to commence in Japan Q4 2020 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020. *TRx calculated from IQVIA unit data (1 month = 1

  26. Slide 26: Japan Phase 2 Study Topline Results

    Slide 26: Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  27. Slide 27: Japan Phase 2 Study Topline Results: IOP

    Slide 27: Japan Phase 2 Study Topline Results: IOP

    P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use

  28. Slide 28: Expanding Aerie Franchise: Europe

    Slide 28: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

  29. Slide 29: Summary Key Priorities

    Slide 29: Summary Key Priorities

    For Investor Use Summary Key Priorities Rhopressa® and Rocklatan® gaining momentum in the United States Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives TRPM8 agonist for dry eye Retina Program Well-Financed $264.7M

Source: SEC EDGAR · 8-K filed Jul 8, 2020

More decks from Aerie Pharmaceuticals Inc.